Next Arc Research

Not logged in? You're viewing the Free tier. Join for free or log in to access your membership content.
Disclaimer: This content is for informational and educational purposes only and should not be construed as financial or investment advice. Always do your own research and consult a licensed financial advisor before making investment decisions.
Disclosure: The author does not hold a position in RXRX.
← Back to Free Index

RXRX

Analysis as of: 2026-03-28
Recursion Pharmaceuticals, Inc.
Clinical-stage biotech using an integrated AI, data, and automated-lab stack to discover and develop internal and partnered medicines.
ai automation biotech healthcare
On Yahoo Finance ...
Jump to: Summary • Analysis • Opportunity • Risk • Trends • LE Structure • Third Party Analyst Consensus

Summary

Clinical proof could unlock a platform re-rate
The upside does not require Recursion to become the dominant AI drug company. It requires enough repeatable clinical and partner proof for investors to value it as a multi-asset engine instead of a cash-rich but unproven platform biotech.

Analysis

Thesis
Recursion is one of the few techbio names with owned wet-lab telemetry, real partner revenue, and enough cash to chase multiple shots on goal; if 2026-2027 milestones prove REC-4881 is not a one-off and the platform keeps producing clinic-worthy assets, the market can re-rate it from cash-burning experiment to repeatable drug-creation engine.
Last Economy Alignment
Cheaper AI helps because Recursion owns the data-generation loop, not just a thin interface, but clinical proof and pharma insourcing still cap the score.
Upgrade to Allocator to also access: Thesis Critique

Opportunity Outlook

Average Implied 5-Year Multiple
5.5x (from 5 most recent analyses)
Reasoning
The upside case is a category shift in how investors frame the business. If one owned asset earns a credible commercial path, at least one more internal program validates platform repeatability, and partnerships become recurring proof of external demand, the company can be valued less like a speculative single-asset biotech and more like a multi-asset discovery engine. That re-rating does not need flawless execution, only enough evidence that its data-and-lab loop repeatedly creates valuable programs.
Upgrade to Allocator to also access: Simplified Opportunity Explanation

Risk Assessment

Overall Risk Summary
This is still a proof-heavy biotech, not a solved software model. The biggest risks are an unfavorable REC-4881 regulatory path, weak follow-on clinical translation, continued cash burn that forces more equity issuance before self-funding, partner concentration, and delayed remediation of internal-control issues that limits trust in the platform story.
Upgrade to Allocator to also access: Tech Maturity Risk Score, Adoption Timing Risk Score, Moat Strength Risk Score, Capital Needs Risk Score, Regulatory Risk Score, Execution Risk Score, Concentration Risk Score, Unit Economics Risk Score, Valuation Risk Score, Macro Sensitivity Risk Score

Last Economy Structure

AI Industrial Score
0.55
They own the labs, data, and workflow that turn cheaper AI into more drug shots on goal, so AI progress can make their machine more productive. The catch is simple: if those programs do not keep working in humans, the advantage stays interesting but not valuable.
Upgrade to Reader to also access: Score Decomposition, Confidence Level
Upgrade to Allocator to also access: Obsolescence Vectors, Pricing Fragility
Upgrade to Reader to also access: Constraint Benefit Score, Obsolescence Risk Score

Third Party Analyst Consensus

12-Month Price Target
$7.20
Upgrade to Reader to also access: Bull Case, Base Case, Bear Case